Elizabeth Swiggum

TL;DR: The 2017 HF guidelines provide updated guidance on the diagnosis and management that should aid in day-to-day decisions for caring for patients with HF, with attention to strategies and treatments to prevent HF, to the organization of HF care, comorbidity management, as well as practical issues around the timing of referral and follow-up care.

TL;DR: The 2012 Canadian Cardiovascular Society Heart Failure (HF) Guidelines Update provides management recommendations for acute and chronic HF and includes recommendations, values and preferences, and practical tips to assist the medical practitioner manage their patients with HF.

TL;DR: The 2011 Canadian Cardiovascular Society Heart Failure Guidelines Focused Update reviews the recently published clinical trials that will potentially impact on management and the important role of palliative care and the need to address end-of-life issues in advanced HF are emphasized.

TL;DR: In this paper, the authors provide comprehensive recommendations and practical tips for the pharmacologic management of patients with heart failure with reduced ejection fraction (HFrEF) including angiotensin receptor-neprilysin inhibitors, sinus node inhibitors, sodium glucose transport 2 inhibitors, and soluble guanylate cyclase stimulators.

TL;DR: It is hoped that the present update will become a useful tool for health care providers and planners in the ongoing evolution of care for HF patients in Canada.